Article
Vorasidenib improves response to subsequent chemoradiation in a genetically engineered mouse model of IDH-mutant glioma.
Science translational medicine - 5 Aug 2026
Shi Diana D, Calvo Fernández Ester, Puliyappadamba Vinesh T, Lanman Tyler A, Xiao Yi, Wen Zebin, Minor Maria, Prost Diego, Lasica Aleksandra B, Cai Feng, Neumann Ethan, Gudipelly Sriram, Clark Louise M, Nguyen Quang-De, Peña Salvador, Wansapura Janaka, Kaphle Pranita, Shipman Tracey, Levitt Michael M, Lin Mathew D, Tsai Alexander C-Y, Lee Joyce H, Cahill Daniel P, Rahman Rifaquat, Haas-Kogan Daphne A, Richardson Timothy E, Tirosh Itay, Jain Payal, Tron Adriana E, Nakhate Vihang, Youssef Gilbert, Dehais Caroline, Jacob Julian, Reardon David A, Miller Julie J, Abdullah Kalil G, Wen Patrick Y, DeBerardinis Ralph J, Xu Lin, Touat Mehdi, Peters Katherine B, Gonzalez Castro L Nicolas, Kaelin William G, Suvà Mario L, McBrayer Samuel K
Abstract excerpt
The mutant isocitrate dehydrogenase 1/2 inhibitor (mIDHi) vorasidenib was recently incorporated into clinical treatment guidelines for IDH-mutant gliomas, although its impact on chemoradiation is unclear. Specifically, it is unknown whether upfront mIDHi exposure alters subsequent chemoradiation efficacy. Addressing this critical question has been challenging because of limited clinical data and a paucity of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.